CYTO - altamiratherapeutics.com Qarzning balans kapitallashuviga nisbati

Altamira Therapeutics Ltd. (CYTO) grafik logotipi

OligoPhore platformasi Altamira Therapeutics (CYTO) uchun RNA dori vositalarini samarali yaratish imkonini beradimi? Ishlab chiqish jarayoni klinik sinovlar va moddalar ishlab chiqarishni tashqi pudratchilarga topshirishga tayanadi; biroq, likvidlik tanqisligi va daromadli mahsulotlarning yo'qligi sezilarli xatarlarni yuzaga keltiradi. Balans kapitaliga nisbatan qarz mablag'larini monitoring qilish qarz yuklamasini vizuallashtiradi, bunda 0.00 joriy metrik ko'rsatkichni tashkil etadi.

CYTO (Altamira Therapeutics Ltd.) Qarzning balans qiymatiga nisbati tarixi 04.07.2022dan 04.01.2025gacha

altamiratherapeutics.com (CYTO) - koʻrsatkichlar kesimi va moliyaviy hisobotlar

- narx va narxlar bo'yicha konsensus prognoz:
Aksiya narxi Altamira Therapeutics Ltd.|CYTO - Tahlilchilar konsensus prognozi
- bozor kapitallashuvi bo'yicha ma'lumotlar:
Bozor qiymati Altamira Therapeutics|CYTO - Qarz va naqd pullar hisobga olingan qiymat
- balans kapitallashuvi bo'yicha ma'lumotlar:
Bitta aksiya uchun sof aktivlar Altamira Therapeutics|CYTO - Kompaniyaning sof aktivlari|Bozor kapitallashuvining balans qiymatiga nisbati altamiratherapeutics.com|CYTO - Kompaniyaning umumiy aktivlari
- qarz va likvidlik bo'yicha ma'lumotlar:
Umumiy qarzning xususiy kapitalga nisbati Altamira Therapeutics|CYTO - Uzoq muddatli qarzning kapitalga koeffitsiyenti|Qisqa muddatli qarzning o'z kapitaliga nisbati Altamira Therapeutics Ltd.|CYTO - Kompaniyaning umumiy yig'indi qarzi|Qarzning balans qiymatiga nisbati Altamira Therapeutics
Kompaniyaning barcha koʻrsatkichlari tahlili:CYTO Auris Medical
Altamira Therapeutics Ltd. asosiy tovari

RNA yetkazib berish sohasida OligoPhore platformasini ishlab chiqayotgan Altamira Therapeutics (CYTO) uchun kompaniyaning kitob kapitalizatsiyasiga nisbatan qarzi moliyaviy leveraj ko'rsatkichi bo'lib xizmat qiladi. Ushbu metrika qarz mablag'larining o'z kapitaliga nisbatan ulushini belgilaydi. Hisob-kitoblar umumiy majburiyatlarning sof aktivlar qiymatiga nisbatiga asoslangan. Bu biofarmatsevtika vositalarini kengaytirish jarayonida startapning tashqi moliyalashtirishga bog'liqligini baholash imkonini beradi. Ushbu ko'rsatkichning barqarorligi kapital tuzilmasining bozor shoklariga chidamliligini tasdiqlaydi.

Altamira Therapeutics raqobatchilari

Balans kapitallashuviga qarzlar HLN (Haleon plc)|kenvue.com - Balans kapitallashuviga qarzlar|Qarzning balans kapitallashuviga nisbati Verona Pharma (VRNA)|MENS: Qarzning sof aktivlarga nisbati|LGND (Ligand Pharma) - Qarzning balans kapitallashuviga nisbati|Amneal Corp (AMRX) - Qarzning balans qiymatiga nisbati|PRGO (Perrigo Company plc) - Balans kapitallashuviga qarzlar|Balans kapitallashuviga qarzlar alvotech.com (ALVO)|Liquidia (LQDA) - Qarzning balans qiymatiga nisbati|Qarzning sof aktivlarga nisbati GLPG (Galapagos N.V.)|ANIP: Qarzning balans kapitallashuviga nisbati|MNKD - Balans qiymatiga qarzlar|Qarzning balans qiymatiga nisbati Amphastar Pharmaceuticals AMPH|PCRX - Qarzning balans kapitaliga nisbati|Balans kapitallashuviga qarzlar ARS Pharmaceuticals, Inc. SPRY|Theravance Biopharma Inc (TBPH) - Qarzning sof aktivlarga nisbati|Balans kapitallashuviga qarzlar AQST (Aquestive Pharma)|Balans qiymatiga qarzlar SCPH|Tectonic Therapeutic, Inc. (TECX) - Qarzning balans kapitallashuviga nisbati|Qarzning sof aktivlarga nisbati tonixpharma.com (TNXP)|Balans kapitallashuviga qarzlar SXTC (China SXT Pharmaceuticals, Inc.)|Eupraxia Pharmaceuticals, Inc. - Balans kapitallashuviga qarzlar|BHST - Qarzning balans kapitallashuviga nisbati|Invizyne (EXOZ) - Qarzning balans kapitallashuviga nisbati|ORMP - Qarzning balans qiymatiga nisbati|Entera Bio (ENTX) - Qarzning balans kapitaliga nisbati|HYFT (MindWalk Holdings Inc.) - Balans kapitallashuviga qarzlar|Balans kapitallashuviga qarzlar ABVC|Qarzning balans kapitallashuviga nisbati CPIX (Cumberland Pharma)|Qarzning balans qiymatiga nisbati Quantum BioPharma Corp (QNTM)|Balans kapitallashuviga qarzlar FGEN|telomirpharma.com - Sof aktivlarga qarzlar|Qarzning balans kapitallashuviga nisbati Rani Therapeutics Inc (RANI)|SNYR - Qarzning sof aktivlarga nisbati|RLYB: Balans kapitallashuviga qarzlar|Balans kapitallashuviga qarzlar Lexaria Bioscience Corp.|PULM - Qarzning balans qiymatiga nisbati|Qarzning sof aktivlarga nisbati Pheton (PTHL)|Qarzning balans qiymatiga nisbati Aptorum Group Limited|Qarzning balans kapitaliga nisbati Lyra Therapeutics Inc. (LYRA)|Balans kapitallashuviga qarzlar Impact BioMedical Inc|Qarzning sof aktivlarga nisbati TNF Pharmaceuticals Inc. TNFA|YCBD (cbdMD Corp) - Balans kapitallashuviga qarzlar|PRFX: Balans qiymatiga qarzlar|Qarzning balans kapitallashuviga nisbati Lipella Pharmaceuticals, Inc. LIPO|OptiNose Inc (OPTN) - Qarzning sof aktivlarga nisbati|PIRS (Pieris) - Balans kapitallashuviga qarzlar|Balans kapitallashuviga qarzlar PROC|PTPI - Qarzning balans kapitallashuviga nisbati|Qarzlarning balans kapitallashuviga nisbati qlsyy.net (QLI)|SLRN: Balans kapitallashuviga qarzlar|TFFP - Balans qiymatiga qarzlar